01177 中國生物製藥
公司資料 - 財務狀況表
中國生物製藥有限公司 股票編號: 01177
SINO BIOPHARMACEUTICAL LTD. 集團網址: http://www.sinobiopharm.com
非流動資產
2025/06 - 中期
人民幣(K¥)
與去年末期
比較
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
投資物業248,619-7.587%269,030289,342720,754705,626
物業、廠房、設備及其他8,493,098-2.281%8,691,3828,080,9077,759,5927,154,298
租賃土地1,560,717-2.258%1,596,7741,831,2541,491,5911,361,764
無形資產3,119,4551.911%3,060,9662,908,9611,914,4501,711,946
聯營公司及共同控制公司權益1,590,863-1.804%1,620,08512,243,67513,198,15714,266,396
其他非流動資產26,061,3362.263%25,484,50114,445,14913,044,83511,840,129
41,074,0880.863%40,722,73839,799,28838,129,37937,040,159
存貨2,103,865-11.347%2,373,1451,993,4722,328,8441,937,741
 
流動資產
現金及銀行結存11,104,40216.039%9,569,5849,451,87812,066,21710,568,812
其他流動資產20,612,05161.757%12,742,60211,447,47511,539,84410,996,625
持作出售資產0--0912,70600
33,820,31837.006%24,685,33123,805,53125,934,90523,503,178
 
流動負債
其他流動負債24,850,61027.071%19,556,49022,367,91620,150,67715,345,019
持作出售資產相關負債0--0238,85900
24,850,61027.071%19,556,49022,606,77520,150,67715,345,019
流動資產淨值8,969,70874.888%5,128,8411,198,7565,784,2288,158,159
資產總額減流動負債50,043,7969.143%45,851,57940,998,04443,913,60745,198,318
 
非流動負債
4,266,08138.621%3,077,5092,828,0915,970,0597,469,295
 
資本及儲備
   股本413,680-0.170%414,384414,615414,899415,440
   儲備32,959,8944.481%31,546,40530,059,85429,332,13629,875,676
   其他0--0000
股東資金33,373,5744.420%31,960,78930,474,46929,747,03530,291,116
非控股權益12,404,14114.712%10,813,2817,695,4848,196,5137,437,907
其他0--0000
45,777,7157.022%42,774,07038,169,95337,943,54837,729,023
 
承擔及或然負債
承擔----1,517,577535,5461,811,239950,038
或然負債----0000
 

Copyright © 2025 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.